KOSDAQBiotech & Pharma087010

Peptron

₩84,600▼ 5.16%2026-11-18 close
Market Cap
₩2T
Turnover
₩14.2B
Volume
160K
Shares out.
23.3M
PER
—
PBR
17.8×
EPS
-₩1,283
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Smart Depot Reaches Market, Losses Keep Widening

Peptron is leaning on the first commercial launch of its SmartDepot platform and the Phase 1 filing for its monthly obesity candidate PT403, yet attributable net losses have widened every quarter since the fourth quarter of 2025, and the timing of licensing revenue remains unclear.

  1. 1

    In July 2025 a leuprorelin-based prostate cancer generic received marketing approval, marking the first commercial use of SmartDepot.

  2. 2

    On the annual filings, 2025 revenue rose 78.8% to KRW 5.63 billion, but the operating loss of KRW 21.3 billion extended a run of losses that has lasted four years.

  3. 3

    Third-quarter 2026 revenue fell 36.8% from a year earlier to KRW 1.01 billion, while the net loss attributable to controlling shareholders widened to KRW 9.31 billion.

  4. 4

    The company said in August 2026 that it had filed an Phase 1 clinical trial plan for PT403 with the Ministry of Food and Drug Safety.

  5. 5

    The outcome of the SmartDepot technology evaluation with Eli Lilly and whether a definitive agreement follows is widely viewed as the key variable for future licensing expectations.

02

Business structure

Peptron is a biotech company whose core is SmartDepot, a long-acting injectable drug delivery platform built on synthetic peptides.

SmartDepot releases drugs gradually in the body, which the company says can extend the effect of short-half-life peptides from one week to six months, using biodegradable polymer microspheres.

A leuprorelin-based prostate cancer generic using the platform received Korean marketing approval in 2025, making it the first commercial use of SmartDepot.

The company attributed the 2025 revenue increase to a larger product lineup following that approval and to higher revenue recognized on a percentage-of-completion basis. Reports also describe technology fee revenue and peptide material sales as drivers of revenue growth.

On the partner side, Peptron signed an MTA with Eli Lilly in October 2024 for a SmartDepot technology evaluation, and reports say it provided technology to Yuhan for once- or twice-weekly GLP-1 diabetes drug development and granted Qilu Pharmaceutical exclusive rights to one antibody-drug conjugate candidate.

Competition in leuprorelin depot generics is significant, since Daewoong Pharmaceutical and Dong-Kook Pharmaceutical brought microsphere-based one-month formulations to Korea earlier, which keeps the technical differentiation claim contested.

The pipeline centers on PT403, a semaglutide-based long-acting injectable targeting monthly dosing.

In August 2026 the company filed a Phase 1 clinical trial plan for PT403 with the Ministry of Food and Drug Safety, planning a single-dose study in 22 healthy adults at Chungnam National University Hospital across three cohorts.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.6B-₩6.2B−389.3%
2025Q4₩1B-₩5.7B−576.4%
2026Q1₩2B-₩5.8B−293.8%
2026Q2₩1.4B-₩7.9B−549.9%
2026Q3₩1B-₩7B−691.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩5.8B-₩15.2B-₩15.1B−261.9%−28.4%28.6%
2023₩3.3B-₩15.9B-₩15.9B−475.3%−44.1%45.3%
2024₩3.2B-₩16.5B-₩22B−524.3%−14.5%11.3%
2025₩5.6B-₩21.3B-₩13.8B−377.3%−9.7%26.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On the annual filings, revenue went from KRW 5.81 billion in 2022 to KRW 3.34 billion in 2023, a 42.5% decline, then to KRW 3.15 billion in 2024, down 5.7%, before rising 78.8% to KRW 5.63 billion in 2025. Among 2022 to 2025, 2022 was the largest year and 2024 the smallest.

Operating losses were KRW 15.2 billion in 2022, KRW 15.9 billion in 2023, KRW 16.5 billion in 2024 and KRW 21.3 billion in 2025, a four-year run of losses in which the loss grew each year after 2022.

The operating margin moved from -261.9% in 2022 and -475.3% in 2023 to -524.3% in 2024 and -377.3% in 2025, improving in 2025 because revenue growth of 78.8% outpaced the roughly 29% increase in operating loss.

Net loss attributable to controlling shareholders went from KRW 15.1 billion in 2022 to KRW 15.9 billion in 2023 and KRW 22 billion in 2024, then narrowed to KRW 13.8 billion in 2025, a divergence from the wider operating loss that points to non-operating items worth examining.

Net loss including non-controlling interests matches the controlling-shareholder figure in every year because there are no non-controlling interests. Operating cash outflow was KRW -11.7 billion in 2022, KRW -11 billion in 2023, KRW -12.8 billion in 2024 and KRW -20.6 billion in 2025, the largest outflow in the period.

The debt ratio rose from 11.3% in 2024 to 26.0% in 2025, with total equity of KRW 142 billion and total liabilities of KRW 37 billion at the end of 2025.

On a quarterly basis, revenue was KRW 1.6 billion in the third quarter of 2025, KRW 987 million in the fourth quarter, KRW 1.97 billion in the first quarter of 2026 at the peak, KRW 1.45 billion in the second quarter and KRW 1.01 billion in the third quarter, with two straight quarterly declines since the first quarter.

Third-quarter 2026 operating loss was KRW 6.99 billion, wider than KRW 6.24 billion a year earlier. Net loss attributable to controlling shareholders grew from KRW 2.02 billion in the third quarter of 2025 to KRW 9.31 billion in the third quarter of 2026, and the four most recent quarters total KRW 27.8 billion.

Because quarterly revenue is volatile, the contribution of non-recurring technology fees should be separated from recurring sales.

05

Industry analysis

Demand for long-acting injectables has grown alongside GLP-1 drugs for obesity and diabetes, and many drugmakers are developing long-acting GLP-1 formulations, which has intensified formulation technology competition.

Daewoong Pharmaceutical's one-month depot product was reported to have recorded KRW 32.5 billion in production in 2023, leading the formulation segment.

In leuprorelin generics, microsphere technology has already been adopted by most developers, so how Peptron proves SmartDepot's technical differentiation remains the central question. Dong-Kook Pharmaceutical has reportedly developed a three-month leuprorelin generic and is running a confirmatory trial.

Eli Lilly has concentrated resources on its oral obesity drug, and reports said injectable external partnerships have fallen down its priorities. AbbVie has also formally pursued long-acting injectable development, so large drugmakers' interest in platform companies continues.

Demand for long-acting formulations is rising, but licensing deals can be delayed or fall through depending on large drugmakers' internal strategies. Peptron is among a small number of Korean platform companies with commercial experience, though its commercial scale is small compared with large biotech companies.

06

Outlook

The company says it is accelerating overseas licensing talks with several global pharmaceutical and biotech companies. The Phase 1 study of PT403, filed in August 2026, is a single-dose study in healthy adults assessing safety, tolerability and pharmacokinetics.

The company plans to build clinical evidence for global development through a formal trial that follows a 2026 ADA pilot study. The goal is to extend the dosing interval of semaglutide from weekly to monthly using SmartDepot, and differentiation from established products will need to be shown in clinical results.

The Eli Lilly technology evaluation was initially reported as about 14 months after the October 2024 MTA, and a correction in December 2025 changed it to up to 24 months. A February 2026 Chosun Biz report said whether a definitive Lilly agreement follows remains unclear.

Counting up to 24 months from the October 2024 agreement, the evaluation period would end in October 2026, so whether a licensing disclosure follows is the next checkpoint.

PT320, a SmartDepot-based cerebrovascular candidate co-developed with Inventia Healthcare of Australia, was reported in earlier coverage to have received FDA IND clearance for a Phase 3 trial. The overseas licensing of Loupone and the clinical progress of PT320 are also items that will shape the licensing outlook.

Current filings show a sales recovery alongside a widening operating loss, so the trend in operating margin in the next annual report is the key item to verify.

07

Valuation

PER
—
PBR
17.8×
ROE
-20.8%
EPS
-₩1,283
BPS
₩5,206
Dividend per share
₩0

Because the last four quarters have been net losses, the price-to-earnings ratio is not calculated. The price-to-book ratio sits in a range where the premium over net assets is large, and the multiple is well above its level in 2022.

Even after total equity increased sharply at the end of 2024, the multiple has stayed high, which some read as a sign that licensing expectations are weighing more on the share price than current earnings. The company does not pay a dividend, so its dividend yield is below the sector average.

A February 2026 Chosun Biz report noted that a platform company with limited commercial results is carrying a large market value on a single licensing expectation. Compared with listed peers that have more commercial products and licensing deals, Peptron's market value is large relative to its revenue scale.

Valuation is likely to shift with licensing disclosures and clinical results, so those events are the reference points for interpreting it.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

First commercial use of SmartDepot

In July 2025 the Ministry of Food and Drug Safety approved Peptron's prostate cancer generic, which was cited as evidence that SmartDepot had moved from development into commercial-scale production.

Shinhan Investment Corp. said at the time that the technology had been validated through commercialization rather than clinical trials. Some observers, however, cautioned that this does not yet prove competitiveness as a long-acting platform.

PT403 enters Phase 1 filing

In August 2026 Peptron said it had filed a Phase 1 trial plan with the Ministry of Food and Drug Safety for PT403, a monthly semaglutide obesity candidate using SmartDepot. The study is designed to assess safety and pharmacokinetics after a single subcutaneous dose in 22 healthy adults. The company says it will build clinical evidence for global development following a 2026 ADA pilot study.

Expanding overseas licensing talks

Peptron says it is accelerating overseas licensing discussions with several global pharmaceutical and biotech companies. The technology evaluation period under the October 2024 MTA with Eli Lilly was extended to up to 24 months through a correction filing.

Supporters argue that if a deal is signed, upfront and technology fee payments could be reflected in quarterly revenue.

09

Bear factors

Losses widening for five straight quarters

Peptron has posted losses for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026, and the net loss attributable to controlling shareholders grew each quarter from KRW 4.68 billion to KRW 9.31 billion.

The four most recent quarters total KRW 27.8 billion in losses attributable to controlling shareholders. Third-quarter 2026 revenue of KRW 1.01 billion fell 36.8% year on year, so revenue swings have not offset the widening loss.

Uncertainty over the Lilly definitive agreement

The Eli Lilly SmartDepot evaluation period was changed to up to 24 months by a correction filing in December 2025, and reports since then have questioned whether a definitive agreement will follow.

Analysts noted that Lilly has focused its resources on its oral obesity drug, pushing injectable external partnerships down its priorities. Chosun Biz pointed out that Peptron's position in the relationship carries limited legal binding force.

Mixed reading of technical differentiation

The company highlights that its generic was the first to demonstrate bioequivalence for a leuprorelin generic.

The Ministry of Food and Drug Safety, however, noted that earlier generic approvals did not require bioequivalence demonstration, so some see the claim as reflecting a change in rules rather than superior technology.

Because microspheres are already used by most leuprorelin generic developers, the question of differentiation remains open.

10

Risk factors

Cash burn and capital capacity

Operating cash outflow widened from KRW -11.7 billion in 2022 to KRW -20.6 billion in 2025. Total equity was KRW 142 billion and total liabilities KRW 37 billion at the end of 2025, with the debt ratio rising from 11.3% in 2024 to 26.0% in 2025. If losses continue, the pace of equity erosion and the need for additional funding will need to be tracked.

Partner dependence and deal delays

Licensing expectations are concentrated on the Eli Lilly evaluation, so a delay or failure to reach a deal could directly affect how results and the share price are read. Changes in Lilly's strategy are outside Peptron's control.

The company's statement that multiple overseas discussions are ongoing needs to be verified through specific contract disclosures.

Quarterly revenue volatility and competition

Quarterly revenue is volatile, moving from KRW 1.6 billion in the third quarter of 2025 to KRW 1.97 billion in the first quarter of 2026 and KRW 1.01 billion in the third quarter of 2026. Competing microsphere-based leuprorelin generics already exist, so price and share competition could intensify. Depending on PT403 clinical results, the development timeline could also be extended.

11

What to watch next

  1. After November 2026 (schedule not disclosed)

    Progress of the three cohorts in the PT403 Phase 1 study and any safety or pharmacokinetic disclosures. Whether later dose cohorts proceed will signal the potential of the long-acting formulation.

  2. After November 2026 (timing undetermined)

    The outcome of the Eli Lilly SmartDepot evaluation and whether a definitive agreement is signed. Counting up to 24 months from the October 2024 MTA, the evaluation period would have ended in October 2026, so any disclosure after that is the key checkpoint.

  3. After November 2026 (timing undetermined)

    Whether overseas distribution agreements for in-house products such as Loupone are disclosed. If deals are signed, the way technology fees appear in quarterly revenue can be checked.

  4. End of March 2027 (annual report filing deadline)

    The confirmed 2026 annual revenue, operating loss and operating cash flow in the annual report. Key points are whether the 2026 operating loss exceeds KRW 21.3 billion in 2025 and whether the fourth-quarter loss trend continues from the third quarter.

12

Overall view

Peptron created its first commercial case for SmartDepot when a leuprorelin-based generic received approval in 2025, and 2025 revenue rose 78.8% to KRW 5.63 billion.

The operating loss, however, reached KRW 21.3 billion that year, extending a four-year run of losses, and the net loss attributable to controlling shareholders has grown each quarter in 2026, with the last four quarters totaling KRW 27.8 billion.

On the pipeline side, Peptron filed a Phase 1 plan for PT403 in August 2026 and says overseas licensing discussions are ongoing. The key Lilly evaluation has not yet been confirmed as leading to a definitive agreement, and uncertainty remains after the correction filing.

Reports have also said the market value leans more on licensing expectations than on current results. The bull case rests on commercial results, clinical progress and licensing potential, while the bear case rests on widening losses, partner dependence and disputes over technical differentiation.

The next items to verify are Phase 1 progress for PT403, the outcome of the Lilly evaluation, and the operating loss trend in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. investing.com
  2. investing.com
  3. comp.wisereport.co.kr
  4. news.nate.com
  5. comp.fnguide.com
  6. catch.co.kr
  7. hankyung.com
  8. v.daum.net
  9. v.daum.net
  10. ebn.co.kr
  11. mpharm.edaily.co.kr
  12. sisajournal-e.com
  13. press9.kr
  14. m.news.nate.com
  15. m.news.nate.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis